Compare Trump Media and Technology Group Corp (DJT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Neurocrine Biosciences Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.3× Trump Media and Technology Group Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DJT | NBIX | |
|---|---|---|
Market Cap | $2.28B | $14.36B |
Volume | 3,148,379 | 1,237,180 |
Sector | Media | Health |
52-Week High | $17.07 | $185.50 |
52-Week Low | $7.06 | $123.10 |
Typical Hold Time | 17 Days | 23 Days |
Enterprise Value | $2.35B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.11, down 1.34% with bearish technical signals. The company reported $3.68M revenue in 2025 but a net loss of $712M, with negative margins and cash flow challenges. Recent news highlights a proposed merger with TAE Technologies and ongoing volatility linked to political developments and strategic shifts.
Outlook remains high-risk due to persistent losses and speculative sentiment. The merger with TAE offers potential diversification into fusion energy, but profitability concerns and insider selling weigh on investor confidence. Key risks include execution hurdles and dependence on political narratives.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
